Clinical Trials Logo

Adenomatous Polyposis Coli clinical trials

View clinical trials related to Adenomatous Polyposis Coli.

Filter by:

NCT ID: NCT00319007 Recruiting - Clinical trials for Adenomatous Polyposis Coli

Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether sulindac and VSL#3 - inulin, either combined or alone, are effective in treating or preventing adenoma development in the ileal anal pouch in patients with familial adenomatous polyposis.

NCT ID: NCT00253812 Recruiting - Clinical trials for Familial Adenomatous Polyposis

Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy

Start date: November 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to establish whether new techniques that may make polyps (adenomas) stand out better from the background help increase the number of polyps visible at sigmoidoscopy (telescope test to look inside large bowel) compared to looking with standard sigmoidoscopy alone.

NCT ID: NCT00248053 Withdrawn - Clinical trials for Familial Adenomatous Polyposis

Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients

Start date: November 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess if curcumin, a commonly used food spice, can regress colorectal adenomatous polyps in patients with familial adenomatous polyposis, an inherited form of colorectal cancer.

NCT ID: NCT00151476 Terminated - Clinical trials for Familial Adenomatous Polyposis (FAP)

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

Start date: November 2004
Phase: Phase 4
Study type: Observational

This is a registry-based observational study assessing clinical outcomes in FAP patients receiving celecoxib compared with historical/concurrent registry patients who have not received celecoxib. Both retrospective and prospective data will be utilized. No sampling methods apply.

NCT ID: NCT00140894 Terminated - Clinical trials for Adenomatous Polyposis Coli

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Start date: August 6, 2002
Phase: Phase 4
Study type: Interventional

A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.

NCT ID: NCT00134758 Active, not recruiting - Clinical trials for Adenomatous Polyposis Coli, Familial

Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients

Start date: October 2004
Phase: Phase 2/Phase 3
Study type: Interventional

Malignant transformation of adenomas of the duodenum is now the leading cause of death in familial adenomatous polyposis (FAP) patients who had a restorative proctocolectomy. Ursodeoxycholic acid (UDCA) modifies the biliary acid profile and could reduce the severity of duodenal adenomas and prevent such transformation.

NCT ID: NCT00033371 Completed - Colorectal Cancer Clinical Trials

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

Start date: December 13, 2001
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well giving celecoxib with or without eflornithine works in preventing colorectal cancer in patients with familial adenomatous polyposis. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib and eflornithine may keep cancer from forming in patients with familial adenomatous polyposis.

NCT ID: NCT00026468 Withdrawn - Colorectal Cancer Clinical Trials

Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis

Start date: July 1999
Phase: Phase 2/Phase 3
Study type: Interventional

RATIONALE: Exisulind may be effective in preventing the development and growth of polyps in patients who have familial adenomatous polyposis. PURPOSE: Randomized phase II/III trial to determine the effectiveness of exisulind in preventing the development and growth of polyps in patients who have familial adenomatous polyposis.